Article Details

FDA panel knocks down Pfizer, Lilly's osteoarthritis pain drug in near-unanimous vote

Retrieved on: 2021-03-25 17:58:17

Tags for this article:

Click the tags to see associated articles and topics

FDA panel knocks down Pfizer, Lilly's osteoarthritis pain drug in near-unanimous vote. View article details on hiswai:

Excerpt

Pfizer and Lilly are seeking approval for tanezumab, a monoclonal antibody that targets nerve growth factor (NGF), for the treatment of osteoarthritis.

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo